Bespoke Biotherapeutics

Bespoke Biotherapeutics is a biotechnology company that specializes in developing engineered B-cell therapeutics, which it terms living drugs. The company utilizes its proprietary platform technologies, such as non-viral, homology-mediated end-joining (HMEJ) using CRISPR/Cas9, to program human B-cells to function as immunotherapies. By sourcing and isolating B-cells and performing site-specific genetic engineering to integrate large transgene cargo, the company aims to create therapies that can traffic to tumors, stimulate T-cells, and express therapeutic proteins like antibodies or cytokines. This approach is designed to overcome limitations inherent in traditional virus-based and cell-based therapies by avoiding chemotherapeutic conditioning and leveraging the distinct protein production and memory functions of B-cells.

These innovations are targeted at addressing significant unmet needs in oncology and rare disease, specifically for patients with high-risk, solid tumor cancers and those with severe hemophilia A. By developing both autologous and off-the-shelf allogeneic product candidates, the company seeks to improve upon current standards of care such as CAR-T therapies and hepatocyte-targeted gene treatments. Bespoke Biotherapeutics has secured significant intellectual property, including granted patents covering its B-cell engineering methodologies, and maintains active research and development efforts, including collaborations at facilities like MBC BioLabs and the University of Minnesota, to advance its programs toward clinical trials.